Adverse Side Effects: Empagliflozin-Related Acute Pancreatitis Case Report.

a sodium-glucose cotransporter 2 inhibitor abdominal pain acute pancreatitis adverse effects drug-related side effects and adverse reactions empagliflozin medications side effects types 2 diabetes

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
27 Dec 2020
Historique:
entrez: 1 2 2021
pubmed: 2 2 2021
medline: 2 2 2021
Statut: epublish

Résumé

Acute pancreatitis is an acute inflammatory process of the pancreas that is associated with multiple etiologies. The two most common causes are gallstones and acute alcohol intoxication. However, medications are often overlooked when determining the cause. Empagliflozin is a type of sodium-glucose transport protein 2 (SGLT-2) inhibitor used for the treatment of type 2 diabetes mellitus. Given that this medication is new, the adverse effects have not been fully reported in the literature. Currently, the most commonly reported side effects are genitourinary infections such as cystitis or yeast infection although acute pancreatitis as a result of empagliflozin is very rare. Here, we discuss a case of a 64-year-old female who presented with severe pancreatitis after recently initiating the use of empagliflozin. Based on the timing of her presentation and her hospital workup to rule out many of the common etiologies, it was concluded that empagliflozin was the likely cause of her acute pancreatitis. With SGLT-2 inhibitors such as empagliflozin, becoming popular as first-line in the management of diabetes, this case may hope to raise awareness of the possible adverse effects related to it. Additionally, this case also emphasizes the importance of identifying iatrogenic related pancreatitis.

Identifiants

pubmed: 33520523
doi: 10.7759/cureus.12325
pmc: PMC7837635
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e12325

Informations de copyright

Copyright © 2020, Zeidan et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Ochsner J. 2015 Spring;15(1):45-51
pubmed: 25829880
Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):73-79
pubmed: 27898586
Gut. 1995 Oct;37(4):565-7
pubmed: 7489946
Drugs. 2018 May;78(7):717-726
pubmed: 29663292
N Am J Med Sci. 2010 May;2(5):211-4
pubmed: 22574290
Drug Des Devel Ther. 2015 Oct 30;9:5793-803
pubmed: 26586935

Auteurs

Bassem S Zeidan (BS)

Internal Medicine, HCA Medical Center of Trinity, Trinity, USA.

Charles Boadu (C)

Internal Medicine, Medical Center of Trinity, Trinity, USA.

Andrea Hernandez (A)

Internal Medicine, HCA Medical Center of Trinity, Trinity, USA.

Johnathan Frunzi (J)

Internal Medicine, Medical Center of Trinity, Trinity, USA.

Itioye Adetula (I)

Internal Medicine, Medical Center of Trinity, Trinity, USA.

Classifications MeSH